A preventive treatment for dementia may proceed to clinical trials after successful animal testing.
The US-led research is looking to develop effective immunotherapy via a new vaccine to remove ‘brain plaque’ and tau protein aggregates linked to Alzheimer’s disease.
Recent success in bigenic mice models supports progression to human trials in years to come, the researchers say.
A new paper in the journal Alzheimer’s Research & Therapy paves the way for more work in 2020, with medical researchers at the Institute for Molecular Medicine and University of California, Irvine (UCI) working with a successful vaccine formulated on adjuvant developed by Flinders University Professor Nikolai Petrovsky in South Australia.
The latest research aims to come up with a new treatment to remove accumulated beta-amyloid (A?) plaques and neurofibrillary tangles composed of hyperphosphorylated tau, which together lead to neurodegeneration and cognitive decline in Alzheimer’s disease.
Alzheimer’s disease (AD) is the leading cause of age-related dementia, affecting about 5.7 million people in the US. Major challenges in AD include the lack of effective treatments, reliable biomarkers, or preventive strategies.
Professor of the Institute for Molecular Medicine Anahit Ghochikyan and colleagues, Associate Professors Hvat Davtyan and Mathew Blurton-Jones from UCI, and other co-authors tested the universal MultiTEP platform-based vaccines formulated in the adjuvant developed at Professor Petrovsky’s Australian lab.
The possible new therapies were tested in bigenic mice with mix A? and tau pathologies.
“Taken together, these findings warrant further development of this dual vaccination strategy based on the MultiTEP technology for ultimate testing in human Alzheimer’s disease,” the lead authors Professor Ghochikyan and Blurton-Jones conclude.
Professor Petrovsky says the Advax adjuvant method is a pivotal system to help take the combination MultiTEP-based A?/tau vaccines therapy, as well as separate vaccines targeting these pathological molecules, to clinical trials – perhaps within two years.
“Our approach is looking to cover all bases and get past previous roadblocks in finding a therapy to slow the accumulation of A?/tau molecules and delay AD progression in a the rising number of people around the world,” says Professor Petrovsky, who will work in the US for the next three months.
Several promising drug candidates have failed in clinical trials so the search for new preventions or therapies continues.
A recent report on human monoclonal antibody, aducanumab, showed that high dose of this antibody reduced clinical decline in patients with early AD as measured by primary and secondary endpoints.
However, it is obvious that it could not be used as a preventive measure in healthy subjects due to the need for frequent (monthly) administration of high concentrations of immunotherapeutic.
Professor Ghochikyan says there is a pressing need to keep searching for new preventive vaccine to delay AD and slow down progression of this devastating disease.
The new combined vaccination approach could potentially be used to induce strong immune responses to both of the hallmark pathologies of AD in a broad population base of vaccinated subjects with high MHC (major histocompatibility complex) class II gene polymorphisms, the new paper concludes.
Go deeper with Bing News on:
- After months of waiting, homebound Mainers starting to get vaccineson April 11, 2021 at 9:30 am
Jane Weber had been "emailing everybody" for weeks desperately seeking COVID-19 vaccinations for herself and her 90-year-old homebound mother, terrified about the consequences should the virus find ...
- After months of waiting, vaccines starting to reach homebound Mainerson April 11, 2021 at 1:00 am
But it's going to take time to inoculate everyone, given the logistics of door-to-door vaccination in such a large, rural state.
- More Black Americans say they are open to getting COVID-19 vaccine after outreach efforts, poll findson April 10, 2021 at 8:59 pm
Like others in her family, Mattie Pringle had doubts about taking the coronavirus vaccine. The 57-year-old Black woman from Myrtle Beach, South Carolina, feared that her high blood pressure and ...
- COVID-19 vaccine shortage impacting some clinics for Iowa colleges and universitieson April 9, 2021 at 5:39 am
The new shortage of the Johnson & Johnson vaccine in Iowa is impacting some large clinics for many colleges and universities.
- Johnson & Johnson vaccine doses will take major drop next weekon April 9, 2021 at 5:30 am
The number of Johnson & Johnson COVID-19 vaccine doses will drop significantly next week, according to Centers for Disease Control and Prevention (CDC) data.
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- Are Vaccine Passports a Freedom or Control?on April 11, 2021 at 10:29 am
This heavily time-limited passport is a temporary incentive rewarding responsible behavior and ensuring fairness by preventing some from free-riding on the immunity of others.
- Whitmer pushes feds for more vaccine doses as COVID cases surge in Michiganon April 11, 2021 at 10:05 am
Washington — As Michigan grapples with a spike in coronavirus cases, Governor Gretchen Whitmer continued to push the Biden administration to send more vaccine doses to the state to combat its ongoing ...
- When should you get the vaccine if you have had Covid-19? Dr. Wen explainson April 11, 2021 at 9:43 am
CNN Medical Analyst Dr. Wen explains when it's safe to get the vaccine after having been diagnosed with Covid-19, plus what to do if you get the virus in between doses.
- Pfizer vaccine may be less effective against South African and UK coronavirus variants, according to Israeli studyon April 11, 2021 at 9:25 am
An Israeli study found that the Pfizer vaccine may not provide full protection against the South African strain. Fully vaccinated patients saw protection against a surging UK strain, but partially ...
- South African variant may evade protection from Pfizer vaccine, Israeli study sayson April 11, 2021 at 9:17 am
(Updates April 10 story with details on plans for a booster shot) By Maayan Lubell JERUSALEM, April 10 (Reuters) - The coronavirus variant discovered in South Africa may evade the protection provided ...